Top

Published in:

Open Access 01-12-2012 | Research

Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma

Authors: Melissa M Alvarez-Downing, Suzanne M Inchauste, Mark E Dudley, Donald E White, John R Wunderlich, Steven A Rosenberg, Udai S Kammula

Published in: World Journal of Surgical Oncology | Issue 1/2012

Abstract

Background

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with metastatic melanoma has been reported to have a 56% overall response rate with 20% complete responders. To increase the availability of this promising therapy in patients with advanced melanoma, a minimally invasive approach to procure tumor for TIL generation is warranted.

Methods

A feasibility study was performed to determine the safety and efficacy of laparoscopic liver resection to generate TIL for ACT. Retrospective review of a prospectively maintained database identified 22 patients with advanced melanoma and visceral metastasis (AJCC Stage M1c) who underwent laparoscopic liver resection between 1 October 2005 and 31 July 2011. The indication for resection in all patients was to receive postoperative ACT with TIL.

Results

Twenty patients (91%) underwent resection utilizing a closed laparoscopic technique, one required hand-assistance and another required conversion to open resection. Median intraoperative blood loss was 100 mL with most cases performed without a Pringle maneuver. Median hospital stay was 3 days. Three (14%) patients experienced a complication from resection with no mortality. TIL were generated from 18 of 22 (82%) patients. Twelve of 15 (80%) TIL tested were found to have in vitro tumor reactivity. Eleven patients (50%) received the intended ACT. Two patients were rendered no evidence of disease after surgical resection, with one undergoing delayed ACT with generated TIL after relapse. Objective tumor response was seen in 5 of 11 patients (45%) who received TIL, with one patient experiencing an ongoing complete response (32+ months).

Conclusions

Laparoscopic liver resection can be performed with minimal morbidity and serve as an effective means to procure tumor to generate therapeutic TIL for ACT to patients with metastatic melanoma.

Available only for authorised users

Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed

Ghosh P, Chin L: Genetics and genomics of melanoma. Expert Rev Dermatol. 2009, 4: 131-10.1586/edm.09.2.PubMedCentralCrossRefPubMed

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001, 19: 3622-3634.PubMed

Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995, 181: 193-201.PubMed

Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL: Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001, 136: 950-955. 10.1001/archsurg.136.8.950.CrossRefPubMed

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999, 17: 2105-2116.PubMed

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000, 18: 158-166.PubMed

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056/NEJMoa1003466.PubMedCentralCrossRefPubMed

Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999, 17: 2745-2751.PubMed

10.

Li Y, McClay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol. 2002, 29: 413-426. 10.1053/sonc.2002.35237.CrossRefPubMed

11.

Rosenberg SA, Yang JC, White DE, Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998, 228: 307-319. 10.1097/00000658-199809000-00004.PubMedCentralCrossRefPubMed

12.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364: 2507-2516. 10.1056/NEJMoa1103782.PubMedCentralCrossRefPubMed

13.

Ribas A, Kim KB, Schuchter LM, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Flaherty KT, Moschos SJ, Lawrence DP, Hersey P, Kefford RF, Chmielowski B, Puzanov I, Li J, Nolop KB, Lee RJ, Joe AK, Sosman JA: BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive melanoma. J Clin Oncol. 2011, 29: supple; abstr 8509-

14.

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research. 2011, 17: 4550-4557. 10.1158/1078-0432.CCR-11-0116.PubMedCentralCrossRefPubMed

15.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002, 298: 850-854. 10.1126/science.1076514.PubMedCentralCrossRefPubMed

16.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005, 23: 2346-2357. 10.1200/JCO.2005.00.240.PubMedCentralCrossRefPubMed

17.

Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008, 26: 5233-5239. 10.1200/JCO.2008.16.5449.PubMedCentralCrossRefPubMed

18.

Rosenberg SA: The emergence of modern cancer immunotherapy. Annals of Surgical Oncology. 2005, 12: 344-346. 10.1245/ASO.2005.01.904.PubMedCentralCrossRefPubMed

19.

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008, 8: 299-308. 10.1038/nrc2355.PubMedCentralCrossRefPubMed

20.

Klapper JA, Davis JL, Ripley RT, Smith FO, Nguyen DM, Kwong KF, Mercedes L, Kemp CD, Mathur A, White DE, Dudley ME, Wunderlich JR, Rosenberg SA, Schrump DS: Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. J Thorac Cardiovasc Surg. 2010, 140: 1276-1282. 10.1016/j.jtcvs.2010.05.020.CrossRefPubMed

21.

Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I: Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Annals of Surgical Oncology. 2010, 17: 163-170. 10.1245/s10434-009-0677-0.CrossRefPubMed

22.

Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003, 26: 332-342. 10.1097/00002371-200307000-00005.PubMedCentralCrossRefPubMed

23.

Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008, 31: 742-751. 10.1097/CJI.0b013e31818403d5.PubMedCentralCrossRefPubMed

24.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB: Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002, 87: 840-845. 10.1038/sj.bjc.6600521.PubMedCentralCrossRefPubMed

25.

Clinical Outcomes of Surgical Therapy Study Group: A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004, 350: 2050-2059.CrossRef

26.

Weller WE, Rosati C: Comparing outcomes of laparoscopic versus open bariatric surgery. Ann Surg. 2008, 248: 10-15. 10.1097/SLA.0b013e31816d953a.CrossRefPubMed

27.

Takata MC, Duh QY: Laparoscopic inguinal hernia repair. Surg Clin North Am. 2008, 88: 157-178. x. 10.1016/j.suc.2007.10.005.CrossRefPubMed

28.

Croome KP, Yamashita MH: Laparoscopic vs open hepatic resection for benign and malignant tumors: An updated meta-analysis. Arch Surg. 2010, 145: 1109-1118.CrossRefPubMed

29.

Tsinberg M, Tellioglu G, Simpfendorfer CH, Walsh RM, Vogt D, Fung J, Berber E: Comparison of laparoscopic versus open liver tumor resection: a case-controlled study. Surg Endosc. 2009, 23: 847-853. 10.1007/s00464-008-0262-9.CrossRefPubMed

30.

Vibert E, Perniceni T, Levard H, Denet C, Shahri NK, Gayet B: Laparoscopic liver resection. Br J Surg. 2006, 93: 67-72. 10.1002/bjs.5150.CrossRefPubMed

31.

Vanounou T, Steel JL, Nguyen KT, Tsung A, Marsh JW, Geller DA, Gamblin TC: Comparing the clinical and economic impact of laparoscopic versus open liver resection. Ann Surg Oncol. 2010, 17: 998-1009. 10.1245/s10434-009-0839-0.PubMedCentralCrossRefPubMed

32.

Mirnezami R, Mirnezami AH, Chandrakumaran K, Abu Hilal M, Pearce NW, Primrose JN, Sutcliffe RP: Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis. HPB (Oxford). 2011, 13: 295-308. 10.1111/j.1477-2574.2011.00295.x.CrossRef

33.

Koffron AJ, Auffenberg G, Kung R, Abecassis M: Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg. 2007, 246: 385-392. 10.1097/SLA.0b013e318146996c. Discussion 392–384PubMedCentralCrossRefPubMed

34.

Buell JF, Thomas MT, Rudich S, Marvin M, Nagubandi R, Ravindra KV, Brock G, McMasters KM: Experience with more than 500 minimally invasive hepatic procedures. Ann Surg. 2008, 248: 475-486.PubMed

35.

Abu Hilal M, Underwood T, Taylor MG, Hamdan K, Elberm H, Pearce NW: Bleeding and hemostasis in laparoscopic liver surgery. Surg Endosc. 2010, 24: 572-577. 10.1007/s00464-009-0597-x.CrossRefPubMed

36.

Gigot JF, Glineur D, Santiago Azagra J, Goergen M, Ceuterick M, Morino M, Etienne J, Marescaux J, Mutter D, van Krunckelsven L, Descottes B, Valleix D, Lachachi F, Bertrand C, Mansvelt B, Hubens G, Saey JP, Schockmel R, Hepatobiliary and Pancreatic Section of the Royal Belgian Society of Surgery and the Belgian Group for Endoscopic Surgery: Laparoscopic liver resection for malignant liver tumors: preliminary results of a multicenter European study. Ann Surg. 2002, 236: 90-97. 10.1097/00000658-200207000-00014.PubMedCentralCrossRefPubMed

37.

Farges O, Jagot P, Kirstetter P, Marty J, Belghiti J: Prospective assessment of the safety and benefit of laparoscopic liver resections. J Hepatobiliary Pancreat Surg. 2002, 9: 242-248. 10.1007/s005340200026.CrossRefPubMed

38.

Morino M, Morra I, Rosso E, Miglietta C, Garrone C: Laparoscopic vs open hepatic resection: a comparative study. Surg Endosc. 2003, 17: 1914-1918. 10.1007/s00464-003-9070-4.CrossRefPubMed

39.

Cannon RM, Brock GN, Marvin MR, Buell JF: Laparoscopic liver resection: an examination of our first 300 patients. J Am Coll Surg. 2011, 213: 501-507. 10.1016/j.jamcollsurg.2011.04.032.CrossRefPubMed

40.

Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I: Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 2010, 17: 163-170. 10.1245/s10434-009-0677-0.CrossRefPubMed

Title: Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma
Authors: Melissa M Alvarez-Downing
Suzanne M Inchauste
Mark E Dudley
Donald E White
John R Wunderlich
Steven A Rosenberg
Udai S Kammula
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-10-113

At a glance: The STEP trials

Springer Medicine

Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Primary clear cell adenocarcinoma of the bladder with recurrence: a case report and literature review

Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status

Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report

Calcification of vestibular schwannoma: a case report and literature review

A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases

Prognostic significance of solitary lymph node metastasis in patients with squamous cell carcinoma of middle thoracic esophagus